Can targeted therapy combinations outperform standard drugs in tough thyroid cancer?

This study looks at how patients with radioiodine-refractory differentiated thyroid cancer are treated in the real world after first-line therapy stops working. It will compare two approaches: a targeted combination (dabrafenib plus trametinib) guided by a specific gene mutation, versus multi-targeted kinase inhibitors that work regardless of mutation status. By analyzing electronic health records of 200 Chinese adults, researchers hope to understand which patients receive which treatments and how long they stay on them. The goal is to inform better treatment decisions for this challenging condition.